

Effect of early intensive multifactorial therapy on 5-year outcomes in individuals with type 2 diabetes detected by screening (SEARCH): a cluster-randomised trial

Lancet, The

378, 156-167

DOI: [10.1016/s0140-6736\(11\)60698-3](https://doi.org/10.1016/s0140-6736(11)60698-3)

Citation Report

#	ARTICLE	IF	CITATIONS
1	New Insights in the Prevention and Early Management of Type 2 Diabetes. Canadian Journal of Diabetes, 2011, 35, 239-241.	0.4	8
2	The case for diabetes screening: ADDITION-Europe. Lancet, The, 2011, 378, 106-108.	6.3	4
3	Screening for diabetes using an oral glucose tolerance test within a western multi-ethnic population identifies modifiable cardiovascular risk: the ADDITION-Leicester study. Diabetologia, 2011, 54, 2237-2246.	2.9	55
5	Glycated hemoglobin A1c(HbA1c) and diabetes: a new era?. Current Medical Research and Opinion, 2011, 27, 7-11.	0.9	6
6	Prevalence of Neuropathy and Peripheral Arterial Disease and the Impact of Treatment in People With Screen-Detected Type 2 Diabetes. Diabetes Care, 2011, 34, 2244-2249.	4.3	89
7	Global Prevention And Control Of Type 2 Diabetes Will Require Paradigm Shifts In Policies Within And Among Countries. Health Affairs, 2012, 31, 84-92.	2.5	32
8	Effectiveness of a diabetes education and self management programme (DESMOND) for people with newly diagnosed type 2 diabetes mellitus: three year follow-up of a cluster randomised controlled trial in primary care. BMJ, The, 2012, 344, e2333-e2333.	3.0	268
9	Comparative effectiveness research for prostate cancer radiation therapy: current status and future directions. Future Oncology, 2012, 8, 37-54.	1.1	13
10	Nonpharmacological interventions for the prevention of type 2 diabetes mellitus. Nature Reviews Endocrinology, 2012, 8, 363-373.	4.3	108
11	Effect of Intensive Multifactorial Treatment Compared With Routine Care on Aortic Stiffness and Central Blood Pressure Among Individuals With Screen-Detected Type 2 Diabetes. Diabetes Care, 2012, 35, 2207-2214.	4.3	24
12	Diabetes Screening Among Immigrants. Diabetes Care, 2012, 35, 754-761.	4.3	40
13	The Management of Type 2 Diabetic Patients with Hypoglycemic Agents. Isrn Endocrinology, 2012, 2012, 1-6.	2.0	1
14	Editorial: Thematic Issue-Topicâ€œDiabetic Cardiovascular Diseaseâ€œAn Unmet Medical Need: Emerging Targets and Therapies-Introduction to the Special Issue. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2012, 10, 185-189.	0.4	1
15	Prevention of microalbuminuria in patients with type 2 diabetes and hypertension. Journal of Hypertension, 2012, 30, 811-818.	0.3	28
17	Should we screen for type 2 diabetes: Yes. BMJ, The, 2012, 345, e4514-e4514.	3.0	17
18	Screening for diabetes. Pathology, 2012, 44, 110-114.	0.3	7
19	Cardiovascular risk reduction following diagnosis of diabetes by screening: 1-year results from the ADDITION-Cambridge trial cohort. British Journal of General Practice, 2012, 62, e396-e402.	0.7	9
20	ADDITION-Europe and the case for diabetes screening. Lancet, The, 2012, 379, 313.	6.3	4

#	ARTICLE	IF	CITATIONS
21	Update on the ROADMAP clinical trial report: olmesartan for the prevention or delay of microalbuminuria development in Type 2 diabetes. <i>Expert Review of Cardiovascular Therapy</i> , 2012, 10, 1087-1092.	0.6	4
22	Association of an Intensive Lifestyle Intervention With Remission of Type 2 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 2489.	3.8	571
23	Apixaban in atrial fibrillation: does predicted risk matter?. <i>Lancet, The</i> , 2012, 380, 1718-1720.	6.3	5
24	Tackling the global diabetes burden: will screening help?. <i>Lancet, The</i> , 2012, 380, 1716-1718.	6.3	15
25	It's NOT FAIR! Or is it? The promise and the tyranny of evidence-based performance assessment. <i>Theoretical Medicine and Bioethics</i> , 2012, 33, 293-311.	0.4	5
26	Screening for hyperglycemia in the developing world: Rationale, challenges and opportunities. <i>Diabetes Research and Clinical Practice</i> , 2012, 98, 199-208.	1.1	25
28	Frequency of Monitoring Diabetes in Primary Care: What Do Well-Controlled Patients Prefer?. <i>Canadian Journal of Diabetes</i> , 2012, 36, 187-192.	0.4	3
29	Standards of Medical Care in Diabetes—2012. <i>Diabetes Care</i> , 2012, 35, S11-S63.	4.3	1,956
30	Screening for type 2 diabetes and population mortality over 10 years (ADDITION-Cambridge): a cluster-randomised controlled trial. <i>Lancet, The</i> , 2012, 380, 1741-1748.	6.3	199
31	A comparison of cost per case detected of screening strategies for Type 2 diabetes and impaired glucose regulation: Modelling study. <i>Diabetes Research and Clinical Practice</i> , 2012, 97, 505-513.	1.1	60
32	Primary care: the custodian of diabetes care?. <i>Practical Diabetes</i> , 2012, 29, 286-291.	0.1	3
33	Screening for type 2 diabetes in a high-risk population: study design and feasibility of a population-based randomized controlled trial. <i>BMC Public Health</i> , 2012, 12, 671.	1.2	13
34	Both cardiovascular and non-cardiovascular comorbidity are related to health status in well-controlled type 2 diabetes patients: a cross-sectional analysis. <i>Cardiovascular Diabetology</i> , 2012, 11, 121.	2.7	34
35	Vascular memory: can we broaden the concept of the metabolic memory?. <i>Cardiovascular Diabetology</i> , 2012, 11, 44.	2.7	27
36	Characteristics of poorly controlled Type 2 diabetes patients in Swiss primary care. <i>Cardiovascular Diabetology</i> , 2012, 11, 70.	2.7	16
37	Does early intensive multifactorial treatment reduce total cardiovascular burden in individuals with screen-detected diabetes? Findings from the ADDITION-Europe cluster-randomized trial. <i>Diabetic Medicine</i> , 2012, 29, e409-16.	1.2	15
38	The Year in Atherothrombosis. <i>Journal of the American College of Cardiology</i> , 2012, 60, 932-942.	1.2	14
39	All-cause mortality and pharmacological treatment intensity following a high risk screening program for diabetes. A 6.6 year follow-up of the ADDITION study, Denmark. <i>Primary Care Diabetes</i> , 2012, 6, 193-200.	0.9	16

#	ARTICLE	IF	CITATIONS
40	The astonishing hypothesis. <i>Primary Care Diabetes</i> , 2012, 6, 341-342.	0.9	0
41	Methodological challenges in designing dementia prevention trials – The European Dementia Prevention Initiative (EDPI). <i>Journal of the Neurological Sciences</i> , 2012, 322, 64-70.	0.3	96
43	Association of Sitting Time and Physical Activity With CKD: A Cross-sectional Study in Family Practices. <i>American Journal of Kidney Diseases</i> , 2012, 60, 583-590.	2.1	48
44	Implementation of the automated Leicester Practice Risk Score in two diabetes prevention trials provides a high yield of people with abnormal glucose tolerance. <i>Diabetologia</i> , 2012, 55, 3238-3244.	2.9	34
45	Protocol for ADDITION-PRO: a longitudinal cohort study of the cardiovascular experience of individuals at high risk for diabetes recruited from Danish primary care. <i>BMC Public Health</i> , 2012, 12, 1078.	1.2	45
46	Diabetic CVD – Soluble Epoxide Hydrolase as A Target. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2012, 10, 212-222.	0.4	14
47	Should we screen for type 2 diabetes? No. <i>BMJ</i> , The, 2012, 345, e4516-e4516.	3.0	12
48	HbA1c in type 2 diabetes diagnostic criteria: addressing the right questions to move the field forwards. <i>Diabetologia</i> , 2012, 55, 1564-1567.	2.9	19
49	Screening for diabetes: hope and despair. <i>Diabetologia</i> , 2012, 55, 1568-1571.	2.9	2
50	The thrifty phenotype hypothesis revisited. <i>Diabetologia</i> , 2012, 55, 2085-2088.	2.9	139
51	Who Should We Target for Diabetes Prevention and Diabetes Risk Reduction?. <i>Current Diabetes Reports</i> , 2012, 12, 147-156.	1.7	21
52	Biomarkers for diabetes prediction, pathogenesis or pharmacotherapy guidance? Past, present and future possibilities. <i>Diabetic Medicine</i> , 2012, 29, 5-13.	1.2	42
53	Diabetes, hyperglycaemia, and acute ischaemic stroke. <i>Lancet Neurology</i> , The, 2012, 11, 261-271.	4.9	377
54	Effect of screening for Type 2 diabetes on population-level self-rated health outcomes and measures of cardiovascular risk: 13-year follow-up of the Ely cohort. <i>Diabetic Medicine</i> , 2012, 29, 886-892.	1.2	23
56	Detection of impaired glucose regulation and/or type 2 diabetes mellitus, using primary care electronic data, in a multiethnic UK community setting. <i>Diabetologia</i> , 2012, 55, 959-966.	2.9	68
57	The clinical characteristics at diagnosis of type 2 diabetes in a multi-ethnic population: the South London Diabetes cohort (SOUL-D). <i>Diabetologia</i> , 2013, 56, 1272-1281.	2.9	61
60	Performance of the UKPDS Outcomes Model for Prediction of Myocardial Infarction and Stroke in the ADDITION-Europe Trial Cohort. <i>Value in Health</i> , 2013, 16, 1074-1080.	0.1	25
61	D�pistage du diab�te de type 1 et de type 2. <i>Canadian Journal of Diabetes</i> , 2013, 37, S373-S376.	0.4	0

#	ARTICLE	IF	CITATIONS
62	Effect of early intensive multifactorial therapy compared with routine care on self-reported health status, general well-being, diabetes-specific quality of life and treatment satisfaction in screen-detected type 2 diabetes mellitus patients (ADDITION-Europe): a cluster-randomised trial. <i>Diabetologia</i> , 2013, 56, 2367-2377.	2.9	18
63	ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. <i>European Heart Journal</i> , 2013, 34, 3035-3087.	1.0	1,758
64	Structured personal care of type 2 diabetes: a 19-year follow-up of the study Diabetes Care in General Practice (DCGP). <i>Diabetologia</i> , 2013, 56, 1243-1253.	2.9	41
65	Diabetic population mortality and cardiovascular risk attributable to hypertension: A decade follow-up from the Tehran Lipid and Glucose Study. <i>Blood Pressure</i> , 2013, 22, 317-324.	0.7	8
66	Diabetes mellitus in Jamaica: sex differences in burden, risk factors, awareness, treatment and control in a developing country. <i>Tropical Medicine and International Health</i> , 2013, 18, 1365-1378.	1.0	38
67	Genezing van diabetes mellitus type 2?. <i>Huisarts En Wetenschap</i> , 2013, 56, 70-73.	0.0	2
71	Should we still screen for type 2 diabetes after ADDITION-Cambridge? A low-income world perspective. <i>Diabetes Research and Clinical Practice</i> , 2013, 100, 282-284.	1.1	2
72	Mitochondrial aldehyde dehydrogenase 2 activation and cardioprotection. <i>Journal of Molecular and Cellular Cardiology</i> , 2013, 55, 58-63.	0.9	23
73	U.S. Preventive Services Task Force Criteria for Diabetes Screening. <i>American Journal of Preventive Medicine</i> , 2013, 45, 246-247.	1.6	2
74	Why We Should Screen for Type 2 Diabetes in High-Risk Patients. <i>American Journal of Preventive Medicine</i> , 2013, 44, S371-S374.	1.6	2
75	Mild depressive symptoms do not influence cognitive functioning in patients with type 2 diabetes. <i>Psychoneuroendocrinology</i> , 2013, 38, 376-386.	1.3	15
76	The development and validation of the Portuguese risk score for detecting type 2 diabetes and impaired fasting glucose. <i>Primary Care Diabetes</i> , 2013, 7, 11-18.	0.9	14
77	Screening for Type 1 and Type 2 Diabetes. <i>Canadian Journal of Diabetes</i> , 2013, 37, S12-S15.	0.4	49
78	The "Test Your Memory" test performs better than the MMSE in a population without known cognitive dysfunction. <i>Journal of the Neurological Sciences</i> , 2013, 328, 92-97.	0.3	26
79	Screening for type 2 diabetes and population mortality over 10 years. <i>Lancet, The</i> , 2013, 381, 902.	6.3	1
80	Changes in physical activity and modelled cardiovascular risk following diagnosis of diabetes: 1-year results from the ADDITION-Cambridge trial cohort. <i>Diabetic Medicine</i> , 2013, 30, 233-238.	1.2	13
81	Hyperglycemia and Vascular Metabolic Memory: Truth or Fiction?. <i>Current Diabetes Reports</i> , 2013, 13, 403-410.	1.7	39
82	Standards of Medical Care in Diabetes—2013. <i>Diabetes Care</i> , 2013, 36, S11-S66.	4.3	3,076

#	ARTICLE	IF	CITATIONS
83	Impact of early detection and treatment of diabetes on the 6-year prevalence of cardiac autonomic neuropathy in people with screen-detected diabetes: ADDITION-Denmark, a cluster-randomised study. <i>Diabetologia</i> , 2013, 56, 101-108.	2.9	55
84	Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. , 2013, , CD008143.		130
85	Three-year effects on dietary quality of health education: a randomized controlled trial of people with screen-detected dysglycaemia (The ADDITION study, Denmark). <i>European Journal of Public Health</i> , 2013, 23, 393-398.	0.1	6
86	Medication Costs by Glucose Tolerance Stage in Younger and Older Women and Men: Results from the Population-based KORA Survey in Germany. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2013, 121, 614-623.	0.6	3
87	Screening for type 2 diabetes does not reduce mortality over 10 years. <i>Evidence-Based Medicine</i> , 2013, 18, e44-e44.	0.6	0
88	Weight control: key to managing "diabesity". <i>British Journal of Diabetes and Vascular Disease</i> , 2013, 13, 7-12.	0.6	1
89	Screening for Diabetes after Stroke and Transient Ischemic Attack. <i>Cerebrovascular Diseases</i> , 2013, 36, 290-291.	0.8	6
90	A prospective study of risk factors for foot ulceration: The West of Ireland Diabetes Foot Study. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2013, 106, 1103-1110.	0.2	54
91	How to screen for diabetes risk in multi-ethnic populations: does one method fit all?. <i>European Diabetes Nursing</i> , 2013, 10, 63-68.	0.2	0
92	"High-risk populations should be screened for "pre-diabetes" and type 2 diabetes". <i>Practical Diabetes</i> , 2013, 30, 233-237a.	0.1	1
93	Feasibility and Effectiveness in Clinical Practice of a Multifactorial Intervention for the Reduction of Cardiovascular Risk in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2013, 36, 2566-2572.	4.3	20
94	Screening for people with glucose metabolism disorders within the framework of the DEMOJUAN project (DEMOstration area for primary prevention of type 2 diabetes, JUAN Mina and Barranquilla,) <i>Tj ETQq1 1 0.784314 rgBT /Over</i>		
95	Screening for diabetes: what do the results of the ADDITION trial mean for clinical practice?. <i>Diabetes Management</i> , 2013, 3, 367-378.	0.5	5
96	Joint Prevalence of Diabetes, Impaired Glucose Regulation, Cardiovascular Disease Risk and Chronic Kidney Disease in South Asians and White Europeans. <i>PLoS ONE</i> , 2013, 8, e55580.	1.1	26
97	Change in cardiovascular risk factors following early diagnosis of type 2 diabetes: a cohort analysis of a cluster-randomised trial. <i>British Journal of General Practice</i> , 2014, 64, e208-e216.	0.7	11
98	Exercise Interventions to Prevent and Manage Type 2 Diabetes: Physiological Mechanisms. <i>Medicine and Sport Science</i> , 2014, 60, 36-47.	1.4	16
99	Impact on short-term glycaemic control of initiating diabetes care versus leaving diabetes untreated among individuals with newly screening-detected diabetes in Japan. <i>Journal of Epidemiology and Community Health</i> , 2014, 68, 1189-1195.	2.0	8
100	Do improvements in dietary behaviour contribute to cardiovascular risk factor reduction over and above cardio-protective medication in newly diagnosed diabetes patients?. <i>European Journal of Clinical Nutrition</i> , 2014, 68, 1113-1118.	1.3	7

#	ARTICLE	IF	CITATIONS
101	Healthy Behavior Change and Cardiovascular Outcomes in Newly Diagnosed Type 2 Diabetic Patients: A Cohort Analysis of the ADDITION-Cambridge Study. <i>Diabetes Care</i> , 2014, 37, 1712-1720.	4.3	40
102	Effect of an Educational Toolkit on Quality of Care: A Pragmatic Cluster Randomized Trial. <i>PLoS Medicine</i> , 2014, 11, e1001588.	3.9	18
103	Considerations in the design of randomized trials to screen for type 2 diabetes. <i>Clinical Trials</i> , 2014, 11, 284-291.	0.7	3
104	Changes in diet, cardiovascular risk factors and modelled cardiovascular risk following diagnosis of diabetes: 1-year results from the <sc>ADDITION</sc>-Cambridge trial cohort. <i>Diabetic Medicine</i> , 2014, 31, 148-155.	1.2	6
105	Does early intensive multifactorial therapy reduce modelled cardiovascular risk in individuals with screen-detected diabetes? Results from the <b>ADDITION</b>-Europe cluster randomized trial. <i>Diabetic Medicine</i> , 2014, 31, 647-656.	1.2	20
106	Effect of a participant-driven health education programme in primary care for people with hyperglycaemia detected by screening: 3-year results from the Ready to Act randomized controlled trial (nested within the ADDITION-Denmark study). <i>Diabetic Medicine</i> , 2014, 31, 976-986.	1.2	12
107	Epidemiology of diabetes. <i>Medicine</i> , 2014, 42, 698-702.	0.2	345
108	Effect of Early Multifactorial Therapy Compared With Routine Care on Microvascular Outcomes at 5 Years in People With Screen-Detected Diabetes: A Randomized Controlled Trial. <i>Diabetes Care</i> , 2014, 37, 2015-2023.	4.3	56
109	Performance of the UKPDS Outcomes Model for Prediction of Myocardial Infarction and Stroke in the ADDITION-Europe Trial Cohort: Does the ADDITION Validation Add Up?. <i>Value in Health</i> , 2014, 17, 895-896.	0.1	1
110	Validation of the IMS CORE Diabetes Model. <i>Value in Health</i> , 2014, 17, 714-724.	0.1	163
111	Understanding the Type 2 Diabetes Mellitus and Cardiovascular Disease Risk Paradox. <i>Postgraduate Medicine</i> , 2014, 126, 190-204.	0.9	11
112	Variation in prescribing of lipid-lowering medication in primary care is associated with incidence of cardiovascular disease and all-cause mortality in people with screen-detected diabetes: findings from the ADDITION -Denmark trial. <i>Diabetic Medicine</i> , 2014, 31, 1577-1585.	1.2	13
113	The ideal blood pressure target to prevent cardiovascular disease in type 2 diabetes: A neutral viewpoint. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2014, 24, 577-584.	1.1	4
114	External validation of two diabetes risk scores in a young UK South Asian population. <i>Diabetes Research and Clinical Practice</i> , 2014, 104, 451-458.	1.1	5
115	Socioeconomic position and cardiovascular risk factors among people with screen-detected Type 2 DM: Six-year follow-up of the ADDITION-Denmark trial. <i>Primary Care Diabetes</i> , 2014, 8, 322-329.	0.9	9
116	Correspondence: Response to Letter to the Editor by K Scharf and J Morton. <i>Obesity Surgery</i> , 2014, 24, 146-147.	1.1	0
117	Cardiovascular Risk in Diabetes Mellitus: Cause and Effect. <i>Current Emergency and Hospital Medicine Reports</i> , 2014, 2, 16-25.	0.6	0
118	Psychological distress, cardiovascular complications and mortality among people with screen-detected type 2 diabetes: follow-up of the ADDITION-Denmark trial. <i>Diabetologia</i> , 2014, 57, 710-717.	2.9	39

#	ARTICLE	IF	CITATIONS
119	Educational group visits for the management of chronic health conditions: A systematic review. <i>Patient Education and Counseling</i> , 2014, 95, 3-29.	1.0	43
120	Diabetes-specific quality of life but not health status is independently associated with glycaemic control among patients with type 2 diabetes: A cross-sectional analysis of the ADDITION-Europe trial cohort. <i>Diabetes Research and Clinical Practice</i> , 2014, 104, 281-287.	1.1	45
121	Guía de práctica clínica de la ESC sobre diabetes, prediabetes y enfermedad cardiovascular, en colaboración con la European Association for the Study of Diabetes. <i>Revista Española De Cardiología</i> , 2014, 67, 136.e1-136.e56.	0.6	15
122	Controversies in Obesity. , 2014, , .		3
123	Self-Reported Prevalence of Diabetes Screening in the U.S., 2005–2010. <i>American Journal of Preventive Medicine</i> , 2014, 47, 780-787.	1.6	28
125	Standards of Medical Care in Diabetes—2014. <i>Diabetes Care</i> , 2014, 37, S14-S80.	4.3	3,893
126	Prevention of macrovascular disease in patients with short-duration type 2 diabetes by multifactorial target control: an 8-year prospective study. <i>Endocrine</i> , 2014, 47, 485-492.	1.1	6
127	The effectiveness of structured personal care of type 2 diabetes on recurrent outcomes: a 19-year follow-up of the study Diabetes Care in General Practice (DCGP). <i>Diabetologia</i> , 2014, 57, 1119-23.	2.9	6
129	The long-term benefits of lifestyle interventions for prevention of diabetes. <i>Lancet Diabetes and Endocrinology</i> , the, 2014, 2, 441-442.	5.5	4
130	Definition of intervention points in prediabetes. <i>Lancet Diabetes and Endocrinology</i> , the, 2014, 2, 667-675.	5.5	52
131	Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. <i>Lancet</i> , The, 2014, 383, 2008-2017.	6.3	194
132	Is There an Effect of Glucose Lowering Treatment on Incidence and Prognosis of Tuberculosis? A Systematic Review. <i>Current Diabetes Reports</i> , 2014, 14, 505.	1.7	14
133	Predictors of hyperglycaemic individuals who do not follow up with physicians after screening in Japan: A cohort study. <i>Diabetes Research and Clinical Practice</i> , 2014, 105, 176-184.	1.1	12
134	Self-reported diabetes treatment among Chinese middle-aged and older adults with diabetes: Comparison of urban residents, migrants in urban settings, and rural residents. <i>International Journal of Nursing Sciences</i> , 2015, 2, 9-14.	0.5	4
135	Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2015, 14, 100.	2.7	206
136	Cost-effectiveness of intensive multifactorial treatment compared with routine care for individuals with screen-detected Type 2 diabetes: analysis of the ADDITION-UK cluster-randomized controlled trial. <i>Diabetic Medicine</i> , 2015, 32, 907-919.	1.2	19
137	The impact of intensive multifactorial treatment on perceptions of chronic care among individuals with screen-detected diabetes: results from the ADDITION-Denmark trial. <i>International Journal of Clinical Practice</i> , 2015, 69, 466-473.	0.8	9
138	Diabetic kidney disease. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15018.	18.1	542



#	ARTICLE	IF	CITATIONS
139	Screening for Abnormal Blood Glucose and Type 2 Diabetes Mellitus: U.S. Preventive Services Task Force Recommendation Statement. <i>Annals of Internal Medicine</i> , 2015, 163, 861-868.	2.0	253
140	Medication burden in the first 5 years following diagnosis of type 2 diabetes: findings from the <i>ADDITION-UK</i> trial cohort. <i>BMJ Open Diabetes Research and Care</i> , 2015, 3, e000075.	1.2	8
143	Baseline diabetes as a way to predict CV outcomes in a lipid-modifying trial: a meta-analysis of 330,376 patients from 47 landmark studies. <i>Cardiovascular Diabetology</i> , 2015, 14, 60.	2.7	3
144	Effect of six years intensified multifactorial treatment on levels of hsCRP and adiponectin in patients with screen detected type 2 diabetes: The <i>ADDITION-Netherlands</i> randomized trial. <i>Diabetes/Metabolism Research and Reviews</i> , 2015, 31, 758-766.	1.7	3
145	Intensive multifactorial treatment modifies the effect of family history of diabetes on glycaemic control in people with Type 2 diabetes: a <i>post hoc</i> analysis of the <i>ADDITION-Denmark</i> randomized controlled trial. <i>Diabetic Medicine</i> , 2015, 32, 1085-1089.	1.2	4
146	Causation in evidence-based medicine: in reply to <i>Kerry et al</i> . <i>Journal of Evaluation in Clinical Practice</i> , 2015, 21, 532-534.	0.9	0
148	Data-analytically derived flexible HbA1c thresholds for type 2 diabetes mellitus diagnostic. <i>Artificial Intelligence Research</i> , 2015, 5, .	0.3	4
149	Population Approaches for Detecting Glucose Disorders. <i>Current Diabetes Reviews</i> , 2015, 12, 42-50.	0.6	4
150	Weight Changes following the Diagnosis of Type 2 Diabetes: The Impact of Recent and Past Weight History before Diagnosis. Results from the Danish Diabetes Care in General Practice (DCGP) Study. <i>PLoS ONE</i> , 2015, 10, e0122219.	1.1	20
151	Target Values of Cardiovascular Risk Factors Are Not Associated with All-Cause Mortality in Patients with Type 2 Diabetes Mellitus. <i>PLoS ONE</i> , 2015, 10, e0124536.	1.1	3
152	New forms of insulin and insulin therapies for the treatment of type 2 diabetes. <i>Lancet Diabetes and Endocrinology</i> , 2015, 3, 638-652.	5.5	84
153	Screening for Type 2 Diabetes Mellitus: A Systematic Review for the U.S. Preventive Services Task Force. <i>Annals of Internal Medicine</i> , 2015, 162, 765-776.	2.0	112
154	The cost-effectiveness of testing strategies for type 2 diabetes: a modelling study. <i>Health Technology Assessment</i> , 2015, 19, 1-80.	1.3	24
155	Early Detection and Treatment of Type 2 Diabetes Reduce Cardiovascular Morbidity and Mortality: A Simulation of the Results of the Anglo-Danish-Dutch Study of Intensive Treatment in People With Screen-Detected Diabetes in Primary Care ( <i>ADDITION-Europe</i> ). <i>Diabetes Care</i> , 2015, 38, 1449-1455.	4.3	214
156	Validating prediction scales of type 2 diabetes mellitus in Spain: the SPREDIA-2 population-based prospective cohort study protocol. <i>BMJ Open</i> , 2015, 5, e007195.	0.8	21
157	Prevalence of Sexual Concerns and Sexual Dysfunction among Sexually Active and Inactive Men and Women with Screen-Detected Type 2 Diabetes. <i>Sexual Medicine</i> , 2015, 3, 302-310.	0.9	19
159	2. Classification and Diagnosis of Diabetes. <i>Diabetes Care</i> , 2015, 38, S8-S16.	4.3	1,471
160	Under-reporting of venous and arterial thrombotic events in randomized clinical trials: a meta-analysis. <i>Internal and Emergency Medicine</i> , 2015, 10, 219-246.	1.0	11

#	ARTICLE	IF	CITATIONS
161	Prevalence of sexual desire and satisfaction among patients with screen-detected diabetes and impact of intensive multifactorial treatment: Results from the ADDITION-Denmark study. <i>Scandinavian Journal of Primary Health Care</i> , 2015, 33, 3-10.	0.6	10
162	Long-Term Effect of Population Screening for Diabetes on Cardiovascular Morbidity, Self-Rated Health, and Health Behavior. <i>Annals of Family Medicine</i> , 2015, 13, 149-157.	0.9	18
163	The Health System and Population Health Implications of Large-Scale Diabetes Screening in India: A Microsimulation Model of Alternative Approaches. <i>PLoS Medicine</i> , 2015, 12, e1001827.	3.9	25
164	Impact of socioeconomic status and gender on glycaemic control, cardiovascular risk factors and diabetes complications in type 1 and 2 diabetes: A population based analysis from a Scottish region. <i>Diabetes and Metabolism</i> , 2015, 41, 145-151.	1.4	42
165	Escalas de cálculo del riesgo cardiovascular para pacientes con diabetes. ¿Qué son y de qué nos sirven?. <i>Avances En Diabetología</i> , 2015, 31, 102-112.	0.1	4
166	Impact of intensive treatment on serum methylglyoxal levels among individuals with screen-detected type 2 diabetes: the ADDITION-Denmark study. <i>Acta Diabetologica</i> , 2015, 52, 929-936.	1.2	8
167	Shared decision making in type 2 diabetes with a support decision tool that takes into account clinical factors, the intensity of treatment and patient preferences: design of a cluster randomised (OPTIMAL) trial. <i>BMC Family Practice</i> , 2015, 16, 27.	2.9	18
168	Cost-Effectiveness Analysis of Incretin Therapy for Type 2 Diabetes in Spain: 1.8mg Liraglutide Versus Sitagliptin. <i>Diabetes Therapy</i> , 2015, 6, 61-74.	1.2	24
170	Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials. <i>Lancet Diabetes and Endocrinology</i> , 2015, 3, 356-366.	5.5	224
171	Validation of the UKPDS 82 risk equations within the Cardiff Diabetes Model. <i>Cost Effectiveness and Resource Allocation</i> , 2015, 13, 12.	0.6	30
172	Evidence Tips the Scale Toward Screening for Hyperglycemia. <i>Diabetes Care</i> , 2015, 38, 1399-1401.	4.3	15
173	The Michigan Model for Coronary Heart Disease in Type 2 Diabetes: Development and Validation. <i>Diabetes Technology and Therapeutics</i> , 2015, 17, 701-711.	2.4	16
174	The role of serum methylglyoxal on diabetic peripheral and cardiovascular autonomic neuropathy: the ADDITION Denmark study. <i>Diabetic Medicine</i> , 2015, 32, 778-785.	1.2	38
175	Evidence-based practice guideline for the treatment for diabetes in Japan 2013. <i>Diabetology International</i> , 2015, 6, 151-187.	0.7	65
176	Glycemic and Cholesterol Control Versus Single-Goal Control in US Veterans with Newly Diagnosed Type 2 Diabetes: A Retrospective Observational Study. <i>Diabetes Therapy</i> , 2015, 6, 339-355.	1.2	2
177	Possible Computer Model for Predicting Cardiovascular Disease in Type 2 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2015, 17, 679-681.	2.4	0
178	Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2015, 373, 2247-2257.	13.9	1,856
179	Management of diabetes in the community. <i>Medicine</i> , 2015, 43, 54-56.	0.2	1

#	ARTICLE	IF	CITATIONS
180	A Narrative Review of Diabetes Intervention Studies to Explore Diabetes Care Opportunities for Pharmacists. <i>Journal of Diabetes Research</i> , 2016, 2016, 1-11.	1.0	15
181	Effects of glucose-lowering and multifactorial interventions on cardiovascular and mortality outcomes: a meta-analysis of randomized control trials. <i>Diabetic Medicine</i> , 2016, 33, 280-289.	1.2	36
182	Mortality and cardiovascular disease outcomes among 740 patients with new-onset Type 2 diabetes detected by screening or clinically diagnosed in general practice. <i>Diabetic Medicine</i> , 2016, 33, 324-331.	1.2	6
183	Use of the Diabetes Medication Choice Decision Aid in patients with type 2 diabetes in Greece: a cluster randomised trial. <i>BMJ Open</i> , 2016, 6, e012185.	0.8	18
184	Effectiveness of a Multicomponent Quality Improvement Strategy to Improve Achievement of Diabetes Care Goals. <i>Annals of Internal Medicine</i> , 2016, 165, 399.	2.0	87
185	Comparison between capillary glucose measured with a Contour glucometer and plasma glucose in a population survey. <i>Laboratoriums Medizin</i> , 2016, 40, 133-139.	0.1	4
186	Effects of intensive glucose lowering in treatment of type 2 diabetes mellitus on cardiovascular outcomes: A meta-analysis of data from 58,160 patients in 13 randomized controlled trials. <i>International Journal of Cardiology</i> , 2016, 218, 50-58.	0.8	51
187	Data analytics identify glycated haemoglobin co-markers for type 2 diabetes mellitus diagnosis. <i>Computers in Biology and Medicine</i> , 2016, 75, 90-97.	3.9	22
188	Silent myocardial ischemia in asymptomatic patients with type 2 diabetes mellitus without previous histories of cardiovascular disease. <i>International Journal of Cardiology</i> , 2016, 216, 151-155.	0.8	9
189	Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial. <i>Cardiovascular Diabetology</i> , 2016, 15, 57.	2.7	34
190	Myocardial dysfunction and cardiovascular disease in type 2 diabetes. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2016, 76, 271-281.	0.6	17
191	Combination therapy for the improvement of long-term macrovascular and microvascular outcomes in type 2 diabetes: Rationale and evidence for early initiation. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 1177-1185.	1.2	15
192	Effect of general health screening and lifestyle counselling on incidence of diabetes in general population: Inter99 randomised trial. <i>Preventive Medicine</i> , 2016, 91, 172-179.	1.6	20
194	Methylglyoxal is associated with changes in kidney function among individuals with screen-detected Type 2 diabetes mellitus. <i>Diabetic Medicine</i> , 2016, 33, 1625-1631.	1.2	40
195	Design of and rationale for the Japan Diabetes Optimal Integrated Treatment study for 3 major risk factors of cardiovascular diseases (J-DOIT3): a multicenter, open-label, randomized, parallel-group trial. <i>BMJ Open Diabetes Research and Care</i> , 2016, 4, e000123.	1.2	26
196	Doubly blind: a systematic review of gender in randomised controlled trials. <i>Global Health Action</i> , 2016, 9, 29597.	0.7	60
197	Statin use and cardiovascular risk factors in diabetic patients developing a first myocardial infarction. <i>Cardiovascular Diabetology</i> , 2016, 15, 81.	2.7	17
198	Cardiovascular Outcomes Trials in Type 2 Diabetes Mellitus. <i>Cardiology</i> , 2016, 135, 108-126.	0.6	5

#	ARTICLE	IF	CITATIONS
199	Clinical Update: Cardiovascular Disease in Diabetes Mellitus. <i>Circulation</i> , 2016, 133, 2459-2502.	1.6	766
200	A systematic review and meta-analysis of glycemic control for the prevention of diabetic foot syndrome. <i>Journal of Vascular Surgery</i> , 2016, 63, 22S-28S.e2.	0.6	92
201	Metabolomic biomarkers for personalised glucose lowering drugs treatment in type 2 diabetes. <i>Metabolomics</i> , 2016, 12, 27.	1.4	30
202	Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease. <i>Nature Reviews Nephrology</i> , 2016, 12, 73-81.	4.1	441
203	Intensive versus conventional glycaemic control for treating diabetic foot ulcers. <i>The Cochrane Library</i> , 2016, 2016, CD010764.	1.5	28
204	2. Classification and Diagnosis of Diabetes. <i>Diabetes Care</i> , 2016, 39, S13-S22.	4.3	917
205	Potential Drug Combinations to Reduce Cardiovascular Disease Burden in Diabetes. <i>Trends in Pharmacological Sciences</i> , 2016, 37, 207-219.	4.0	12
206	Representation of people of South Asian origin in cardiovascular outcome trials of glucose-lowering therapies in Type 2 diabetes. <i>Diabetic Medicine</i> , 2017, 34, 64-68.	1.2	26
207	Cardiovascular risk factors and incident albuminuria in screen-detected type 2 diabetes. <i>Diabetes/Metabolism Research and Reviews</i> , 2017, 33, e2877.	1.7	2
208	Does training of general practitioners for intensive treatment of people with screen-detected diabetes have a spillover effect on mortality and cardiovascular morbidity in "at risk" individuals with normoglycaemia? Results from the ADDITION-Denmark cluster-randomised controlled trial. <i>Diabetologia</i> , 2017, 60, 1016-1021.	2.9	5
209	The potential and pitfalls of GLP-1 receptor agonists for renal protection in type 2 diabetes. <i>Diabetes and Metabolism</i> , 2017, 43, 2S20-2S27.	1.4	68
210	An Interrupted Time Series Analysis to Determine the Effect of an Electronic Health Record-Based Intervention on Appropriate Screening for Type 2 Diabetes in Urban Primary Care Clinics in New York City. <i>Diabetes Care</i> , 2017, 40, 1058-1064.	4.3	21
211	Atherosclerosis associated with dynamic inflammation changes after multifactorial intervention in short-duration type 2 diabetes: A randomized, controlled, 10-year follow-up trial. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 1286-1292.	1.2	11
212	Interventions in type 2 diabetes mellitus and cardiovascular mortality—An overview of clinical trials. <i>European Journal of Internal Medicine</i> , 2017, 42, 1-15.	1.0	11
213	Effectiveness of chronic care models for the management of type 2 diabetes mellitus in Europe: a systematic review and meta-analysis. <i>BMJ Open</i> , 2017, 7, e013076.	0.8	45
214	2. Classification and Diagnosis of Diabetes. <i>Diabetes Care</i> , 2017, 40, S11-S24.	4.3	1,420
215	Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 951-964.	5.5	228
217	Effect of screening for type 2 diabetes on risk of cardiovascular disease and mortality: a controlled trial among 139,075 individuals diagnosed with diabetes in Denmark between 2001 and 2009. <i>Diabetologia</i> , 2017, 60, 2192-2199.	2.9	51

#	ARTICLE	IF	CITATIONS
218	Effect of population screening for type 2 diabetes and cardiovascular risk factors on mortality rate and cardiovascular events: a controlled trial among 1,912,392 Danish adults. <i>Diabetologia</i> , 2017, 60, 2183-2191.	2.9	35
219	Should we screen for type 2 diabetes among asymptomatic individuals? Yes. <i>Diabetologia</i> , 2017, 60, 2148-2152.	2.9	16
220	Incremental Costs and Cost Effectiveness of Intensive Treatment in Individuals with Type 2 Diabetes Detected by Screening in the ADDITION-UK Trial: An Update with Empirical Trial-Based Cost Data. <i>Value in Health</i> , 2017, 20, 1288-1298.	0.1	11
221	Primary Prevention of Cardiovascular Disease in Diabetes Mellitus. <i>Journal of the American College of Cardiology</i> , 2017, 70, 883-893.	1.2	125
223	Does the evidence support population-wide screening for type 2 diabetes? No. <i>Diabetologia</i> , 2017, 60, 2153-2156.	2.9	6
224	Type 2 diabetes in general practice in Norway 2005-2014: moderate improvements in risk factor control but still major gaps in complication screening. <i>BMJ Open Diabetes Research and Care</i> , 2017, 5, e000459.	1.2	35
225	A Decade of Genetic and Metabolomic Contributions to Type 2 Diabetes Risk Prediction. <i>Current Diabetes Reports</i> , 2017, 17, 135.	1.7	19
226	Diabetes in sub-Saharan Africa: from clinical care to health policy. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 622-667.	5.5	328
227	Effectiveness of shared goal setting and decision making to achieve treatment targets in type 2 diabetes patients: A cluster-randomized trial (OPTIMAL). <i>Health Expectations</i> , 2017, 20, 1172-1180.	1.1	19
228	Poor uptake of an online intervention in a cluster randomised controlled trial of online diabetes education for rural general practitioners. <i>Trials</i> , 2017, 18, 137.	0.7	12
229	Effects of glucose-lowering agents on ischemic stroke. <i>World Journal of Diabetes</i> , 2017, 8, 270.	1.3	4
230	Review: Biomarkers and Role in the Prediction and Detection of Type 2 Diabetes and Its Complications. <i>Biomarkers Journal</i> , 2017, 3, .	0.2	2
231	Effects of 50 mg vildagliptin twice daily &lt;i>vs.</i> 50 mg sitagliptin once daily on blood glucose fluctuations evaluated by long-term self-monitoring of blood glucose. <i>Endocrine Journal</i> , 2017, 64, 417-424.	0.7	7
232	Model for Risk-Based Screening of Diabetic Retinopathy in People With Newly-Diagnosed Type 2 Diabetes Mellitus. , 2017, 58, BIO99.		16
233	Risk Factors for Incident Diabetic Polyneuropathy in a Cohort With Screen-Detected Type 2 Diabetes Followed for 13 Years: ADDITION-Denmark. <i>Diabetes Care</i> , 2018, 41, 1068-1075.	4.3	146
234	Diabetes research in primary care: fiction, reality or essential?. <i>Diabetic Medicine</i> , 2018, 35, 832-834.	1.2	3
235	Thresholds and Targets for Hypertension Management in Adults With Type 2 Diabetes Should Remain at 130/80 mmHg: What's the Evidence?. <i>Canadian Journal of Diabetes</i> , 2018, 42, 166-172.	0.4	3
236	Cluster-randomized controlled trials evaluating complex interventions in general practices are mostly ineffective: a systematic review. <i>Journal of Clinical Epidemiology</i> , 2018, 94, 85-96.	2.4	11

#	ARTICLE	IF	CITATIONS
237	Screening for Diabetes and Prediabetes. <i>Endocrinology</i> , 2018, , 1-33.	0.1	1
238	Effect of screening for type 2 diabetes on healthcare costs: a register-based study among 139,075 individuals diagnosed with diabetes in Denmark between 2001 and 2009. <i>Diabetologia</i> , 2018, 61, 1306-1314.	2.9	19
239	Prevention of cardiovascular disease through reduction of glycaemic exposure in type 2 diabetes: <sc>A</sc> perspective on glucose-lowering interventions. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 238-244.	2.2	58
240	Prediction of Type 2 Diabetes by Hemoglobin A1c in Two Community-Based Cohorts. <i>Diabetes Care</i> , 2018, 41, 60-68.	4.3	21
241	Prevalence of micro- and macrovascular diabetes complications at time of type 2 diabetes diagnosis and associated clinical characteristics: A cross-sectional baseline study of 6958 patients in the Danish DD2 cohort. <i>Journal of Diabetes and Its Complications</i> , 2018, 32, 34-40.	1.2	82
242	Predictors of undiagnosed prevalent type 2 diabetes â€” The Danish General Suburban Population Study. <i>Primary Care Diabetes</i> , 2018, 12, 13-22.	0.9	13
243	Five-Year Cost-effectiveness of the Multidisciplinary Risk Assessment and Management Programme â€” Diabetes Mellitus (RAMP-DM). <i>Diabetes Care</i> , 2018, 41, 250-257.	4.3	42
244	2. Classification and Diagnosis of Diabetes: <i>Standards of Medical Care in Diabetesâ€”2018</i>. <i>Diabetes Care</i> , 2018, 41, S13-S27.	4.3	2,534
245	Effectiveness of individual strategies for the empowerment of patients with diabetes mellitus: A systematic review with meta-analysis. <i>Primary Care Diabetes</i> , 2018, 12, 97-110.	0.9	31
246	Five-Year Effectiveness of the Multidisciplinary Risk Assessment and Management Programme â€” Diabetes Mellitus (RAMP-DM) on Diabetes-Related Complications and Health Service Uses â€” A Population-Based and Propensity-Matched Cohort Study. <i>Diabetes Care</i> , 2018, 41, 49-59.	4.3	82
247	Impact of a multifactorial treatment programme on clinical outcomes and cardiovascular risk estimates: a retrospective cohort study from a specialised diabetes centre in Denmark. <i>BMJ Open</i> , 2018, 8, e019214.	0.8	15
248	Back to basics with active lifestyles: exercise is more effective than metformin to reduce cardiovascular risk in older adults with type 2 diabetes. <i>Biology of Sport</i> , 2018, 35, 363-372.	1.7	5
250	Risk Factors for the Presence and Progression of Cardiovascular Autonomic Neuropathy in Type 2 Diabetes: ADDITION-Denmark. <i>Diabetes Care</i> , 2018, 41, 2586-2594.	4.3	67
251	How good are GPs at adhering to a pragmatic trial protocol in primary care? Results from the ADDITION-Cambridge cluster-randomised pragmatic trial. <i>BMJ Open</i> , 2018, 8, e015295.	0.8	3
252	Effects of intensive interventions compared to standard care in people with type 2 diabetes and microalbuminuria on risk factors control and cardiovascular outcomes: A systematic review and meta-analysis of randomised controlled trials. <i>Diabetes Research and Clinical Practice</i> , 2018, 146, 76-84.	1.1	12
253	Screening for Diabetes and Prediabetes. <i>Endocrinology</i> , 2018, , 369-400.	0.1	2
254	Glucose dysregulation phenotypes â€” time to improve outcomes. <i>Nature Reviews Endocrinology</i> , 2018, 14, 632-633.	4.3	6
255	Cardiovascular Risk Factors in a Suburban Community in Nigeria. <i>International Journal of Hypertension</i> , 2018, 2018, 1-6.	0.5	9

#	ARTICLE	IF	CITATIONS
256	Risk-Factor Trajectories Preceding Diabetic Polyneuropathy: ADDITION-Denmark. <i>Diabetes Care</i> , 2018, 41, 1955-1962.	4.3	25
257	Screening for Diabetes in Adults. <i>Canadian Journal of Diabetes</i> , 2018, 42, S16-S19.	0.4	62
259	Optimal search strategies for identifying moderators and predictors of treatment effects in PubMed. <i>Health Information and Libraries Journal</i> , 2019, 36, 318-340.	1.3	3
260	Effects of coenzyme Q10 intervention on diabetic kidney disease. <i>Medicine (United States)</i> , 2019, 98, e15850.	0.4	22
261	Short term optimization of glycaemic control using insulin improves sympatho-vagal tone activities in patients with type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2019, 157, 107875.	1.1	6
262	Addressing Regional Differences in Diabetes Progression: Global Calibration for Diabetes Simulation Model. <i>Value in Health</i> , 2019, 22, 1402-1409.	0.1	13
263	Pathways of Prevention: A Scoping Review of Dietary and Exercise Interventions for Neurocognition. <i>Brain Plasticity</i> , 2019, 5, 3-38.	1.9	18
264	Opportunities for improving use of evidence-based therapy in patients with type 2 diabetes and cardiovascular disease. <i>Clinical Cardiology</i> , 2019, 42, 1063-1070.	0.7	7
265	Prospective Study of Neuropathic Symptoms Preceding Clinically Diagnosed Diabetic Polyneuropathy: ADDITION-Denmark. <i>Diabetes Care</i> , 2019, 42, 2282-2289.	4.3	13
266	The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia. <i>Advances in Therapy</i> , 2019, 36, 2034-2051.	1.3	11
267	Risk of Statin-Induced Hypertransaminasemia. <i>Mayo Clinic Proceedings Innovations, Quality &amp; Outcomes</i> , 2019, 3, 131-140.	1.2	5
268	Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting. <i>Diabetes Therapy</i> , 2019, 10, 1297-1317.	1.2	23
269	A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA. <i>Advances in Therapy</i> , 2019, 36, 1190-1199.	1.3	7
270	The Importance and Role of Multiple Risk Factor Control in Type 2 Diabetes. <i>Current Cardiology Reports</i> , 2019, 21, 35.	1.3	14
271	Validity of Danish register diagnoses of myocardial infarction and stroke against experts in people with screen-detected diabetes. <i>BMC Public Health</i> , 2019, 19, 228.	1.2	6
272	2. Classification and Diagnosis of Diabetes: <i>Standards of Medical Care in Diabetesâ€”2019</i>. <i>Diabetes Care</i> , 2019, 42, S13-S28.	4.3	2,164
273	Long-term effects of intensive multifactorial therapy in individuals with screen-detected type 2 diabetes in primary care: 10-year follow-up of the ADDITION-Europe cluster-randomised trial. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 925-937.	5.5	39
274	Factors influencing harmonized health data collection, sharing and linkage in Denmark and Switzerland: A systematic review. <i>PLoS ONE</i> , 2019, 14, e0226015.	1.1	21

#	ARTICLE	IF	CITATIONS
275	ADDITION-Europe: the first decade and beyond. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 891-893.	5.5	2
276	The utility of a point-of-care sural nerve conduction device for detection of diabetic polyneuropathy: A cross-sectional study. <i>Muscle and Nerve</i> , 2019, 59, 187-193.	1.0	9
277	Effects of one-legged high-intensity interval training on insulin-mediated skeletal muscle glucose homeostasis in patients with type 2 diabetes. <i>Acta Physiologica</i> , 2019, 226, e13245.	1.8	40
278	Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes: A Long-Term Cost-Effectiveness Analysis in Estonia. <i>Diabetes Therapy</i> , 2019, 10, 159-176.	1.2	11
279	Effect of glycaemic control on cardiovascular disease in individuals with type 2 diabetes with pre-existing cardiovascular disease: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 732-735.	2.2	12
280	Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 611-621.	2.2	35
281	Intensive versus standard multifactorial cardiovascular risk factor control in screen-detected type 2 diabetes: 5-year and longer-term modelled outcomes of the ADDITION-Leicester study. <i>Diabetes/Metabolism Research and Reviews</i> , 2019, 35, e3111.	1.7	11
282	The Association of Cardio-Ankle Vascular Index and Ankle-Brachial Index with Macroangiopathy in Patients with Type 2 Diabetes Mellitus. <i>Journal of Atherosclerosis and Thrombosis</i> , 2019, 26, 616-623.	0.9	7
283	Cost-effectiveness of a primary care multidisciplinary Risk Assessment and Management Program for patients with diabetes mellitus (RAMP-DM) over lifetime. <i>Endocrine</i> , 2019, 63, 259-269.	1.1	5
284	Estimates of prediabetes and undiagnosed type 2 diabetes in Denmark: The end of an epidemic or a diagnostic artefact?. <i>Scandinavian Journal of Public Health</i> , 2020, 48, 106-112.	1.2	29
285	Assessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting: Once-weekly semaglutide versus empagliflozin. <i>Journal of Medical Economics</i> , 2020, 23, 193-203.	1.0	17
286	Risk of dementia and cognitive dysfunction in individuals with diabetes or elevated blood glucose. <i>Epidemiology and Psychiatric Sciences</i> , 2020, 29, e43.	1.8	24
287	Effect of a multicomponent intervention on achievement and improvements in quality-of-care indices among people with Type 2 diabetes in South Asia: the CARRS trial. <i>Diabetic Medicine</i> , 2020, 37, 1825-1831.	1.2	3
288	Behaviour change, weight loss and remission of Type 2 diabetes: a community-based prospective cohort study. <i>Diabetic Medicine</i> , 2020, 37, 681-688.	1.2	49
289	Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme. <i>Diabetes Therapy</i> , 2020, 11, 259-277.	1.2	34
290	Factors associated with attendance at clinical follow-up of a cohort with screen-detected type 2 diabetes: ADDITION-Denmark. <i>Primary Care Diabetes</i> , 2020, 14, 239-245.	0.9	3
291	Atorvastatin associated with gamma glutamyl transpeptidase elevation in a hyperlipidemia patient. <i>Medicine (United States)</i> , 2020, 99, e22572.	0.4	7
292	Socio-demographic and modifiable risk factors of diabetes and hypertension among resource constrained patients from rural areas in Mdantsane Township in South Africa. <i>African Health Sciences</i> , 2020, 20, 1344-1354.	0.3	3



#	ARTICLE	IF	CITATIONS
293	Uses and Limitations of the Restricted Mean Survival Time: Illustrative Examples From Cardiovascular Outcomes and Mortality Trials in Type 2 Diabetes. <i>Annals of Internal Medicine</i> , 2020, 172, 541.	2.0	53
294	The Lancet Commission on diabetes: using data to transform diabetes care and patient lives. <i>Lancet</i> , The, 2020, 396, 2019-2082.	6.3	327
295	In screen-detected type 2 diabetes, intensive therapy did not differ from usual care for CV events at 10 years. <i>Annals of Internal Medicine</i> , 2020, 172, JC41.	2.0	1
296	Provision of services in primary care for type 2 diabetes: a qualitative study with patients, GPs, and nurses in the East of England. <i>British Journal of General Practice</i> , 2020, 70, e668-e675.	0.7	6
297	Organisation of primary diabetes care in people with type 2 diabetes in relation to all-cause mortality: A nationwide register-based cohort study. <i>Diabetes Research and Clinical Practice</i> , 2020, 167, 108352.	1.1	1
298	2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes 2020. <i>Diabetes Care</i> , 2020, 43, S14-S31.	4.3	2,192
299	Population-based screen-detected type 2 diabetes mellitus is associated with less need for insulin therapy after 10 years. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e000949.	1.2	4
300	Draft FDA guidance for assessing the safety of glucose lowering therapies: a missed opportunity?. <i>Lancet Diabetes and Endocrinology</i> , the, 2020, 8, 810-811.	5.5	4
301	Effect of a Collaborative Care Model on Depressive Symptoms and Glycated Hemoglobin, Blood Pressure, and Serum Cholesterol Among Patients With Depression and Diabetes in India. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 651.	3.8	73
302	Clinical and cost-effectiveness of a diabetes education and behavioural weight management programme versus a diabetes education programme in adults with a recent diagnosis of type 2 diabetes: study protocol for the Glucose Lowering through Weight management (GLoW) randomised controlled trial. <i>BMJ Open</i> , 2020, 10, e035020.	0.8	2
303	Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials. <i>Lancet Diabetes and Endocrinology</i> , the, 2020, 8, 418-435.	5.5	105
304	Screening for type 2 diabetes mellitus. <i>The Cochrane Library</i> , 2020, 2020, CD005266.	1.5	30
305	Patient-reported outcomes after 10-year follow-up of intensive, multifactorial treatment in individuals with screen-detected type 2 diabetes: the ADDITION-Europe trial. <i>Diabetic Medicine</i> , 2020, 37, 1509-1518.	1.2	1
306	Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 3025-3035.	1.8	22
307	Legacy effect of intensive glucose control on major adverse cardiovascular outcome: Systematic review and meta-analyses of trials according to different scenarios. <i>Metabolism: Clinical and Experimental</i> , 2020, 110, 154308.	1.5	41
308	Advanced Techniques for Predicting the Future Progression of Type 2 Diabetes. <i>IEEE Access</i> , 2020, 8, 120537-120547.	2.6	18
310	Evaluation of the Diabetes Screening Component of a National Cardiovascular Risk Assessment Programme in England: a Retrospective Cohort Study. <i>Scientific Reports</i> , 2020, 10, 1231.	1.6	14
311	The Short-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin and Once-Weekly Dulaglutide for the Treatment of Patients with Type 2 Diabetes: A Cost of Control Analysis in Spain. <i>Diabetes Therapy</i> , 2020, 11, 509-521.	1.2	8

#	ARTICLE	IF	CITATIONS
312	Influence of pre-treatment blood pressure levels on antihypertensive drug benefits in diabetics: the roadmap experience. <i>Blood Pressure</i> , 2020, 29, 247-255.	0.7	0
313	A disease state approach to the pharmacological management of Type 2 diabetes in primary care: A position statement by Primary Care Diabetes Europe. <i>Primary Care Diabetes</i> , 2021, 15, 31-51.	0.9	27
314	Primary care experience and remission of type 2 diabetes: a population-based prospective cohort study. <i>Family Practice</i> , 2021, 38, 140-145.	0.8	8
315	Screening of undiagnosed hyperglycaemia in the dental setting: The <i>DiabetRisk</i> study. A field trial. <i>Journal of Clinical Periodontology</i> , 2021, 48, 378-388.	2.3	9
316	Association of weight loss and weight loss maintenance following diabetes diagnosis by screening and incidence of cardiovascular disease and all-cause mortality: An observational analysis of the ADDITION-Europe trial. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 730-741.	2.2	6
317	2. Classification and Diagnosis of Diabetes:<i>Standards of Medical Care in Diabetesâ€™2021</i>. <i>Diabetes Care</i> , 2021, 44, S15-S33.	4.3	1,794
318	Factors affecting achievement of glycemic targets among type 2 diabetes patients in South Asia: Analysis of the CARRS trial. <i>Diabetes Research and Clinical Practice</i> , 2021, 171, 108555.	1.1	7
319	Multifactorial intervention has a significant effect on diabetic kidney disease in patients with type 2 diabetes. <i>Kidney International</i> , 2021, 99, 256-266.	2.6	46
321	A Target HbA1c Between 7 and 7.7% Reduces Microvascular and Macrovascular Events in T2D Regardless of Duration of Diabetes: a Meta-Analysis of Randomized Controlled Trials. <i>Diabetes Therapy</i> , 2021, 12, 1661-1676.	1.2	6
322	Peri-renal adipose inflammation contributes to renal dysfunction in a non-obese prediabetic rat model: Role of anti-diabetic drugs. <i>Biochemical Pharmacology</i> , 2021, 186, 114491.	2.0	19
323	The long-term cost-effectiveness of oral semaglutide in the Netherlands based on the PIONEER 2, 3 and 4 randomized controlled trials. <i>Diabetes Research and Clinical Practice</i> , 2021, 175, 108759.	1.1	7
324	EURASIAN ASSOCIATION OF CARDIOLOGY (EAC) GUIDELINES FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES IN PATIENTS WITH DIABETES AND PREDIABETES (2021). <i>Eurasian Heart Journal</i> , 2021, , 6-61.	0.2	9
325	Targeting Common Signaling Pathways for the Treatment of Stroke and Alzheimerâ€™s: a Comprehensive Review. <i>Neurotoxicity Research</i> , 2021, 39, 1589-1612.	1.3	8
326	Machine Learning Approaches to Predict Risks of Diabetic Complications and Poor Glycemic Control in Nonadherent Type 2 Diabetes. <i>Frontiers in Pharmacology</i> , 2021, 12, 665951.	1.6	20
327	Inference on win ratio for cluster-randomized semi-competing risk data. <i>Japanese Journal of Statistics and Data Science</i> , 2021, 4, 1263.	0.7	4
328	Modification of cardiovascular disease risk by health behaviour change following type 2 diabetes diagnosis. <i>Diabetic Medicine</i> , 2021, 38, e14646.	1.2	4
329	Screening for Prediabetes and Type 2 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 736.	3.8	223
330	Screening for Prediabetes and Type 2 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 744.	3.8	40

#	ARTICLE	IF	CITATIONS
331	Comparative effectiveness of team-based care with a clinical decision support system versus team-based care alone on cardiovascular risk reduction among patients with diabetes: Rationale and design of the D4C trial. <i>American Heart Journal</i> , 2021, 238, 45-58.	1.2	6
332	Screening for Diabetes and Prediabetes. <i>Endocrinology and Metabolism Clinics of North America</i> , 2021, 50, 369-385.	1.2	26
333	<i>Epidemiology of Diabetes.</i> , 2014, , 2429-2467.		2
334	The Use of Behavior Change Theories in Dietetics Practice in Primary Health Care: A Systematic Review of Randomized Controlled Trials. <i>Journal of the Academy of Nutrition and Dietetics</i> , 2020, 120, 1172-1197.	0.4	41
336	Factors influencing harmonized health data collection, sharing and linkage in Denmark and Switzerland: A systematic review. <i>PLoS ONE</i> , 2019, 14, e0226015.	1.1	1
337	Does Training and Support of General Practitioners in Intensive Treatment of People with Screen-Detected Diabetes Improve Medication, Morbidity and Mortality in People with Clinically-Diagnosed Diabetes? Investigation of a Spill-Over Effect in a Cluster RCT. <i>PLoS ONE</i> , 2017, 12, e0170697.	1.1	1
338	&lt;p&gt;Feasibility Study of Advanced Cardiovascular Screening in Middle-Aged Patients with Diabetes&lt;/p&gt;. <i>Clinical Epidemiology</i> , 2020, Volume 12, 447-455.	1.5	5
339	Metabolic Syndrome and Cardiometabolic Risk Factors. <i>Current Vascular Pharmacology</i> , 2014, 11, 858-879.	0.8	49
340	A Low-Intensity Mobile Health Intervention With and Without Health Counseling for Persons With Type 2 Diabetes, Part 1: Baseline and Short-Term Results From a Randomized Controlled Trial in the Norwegian Part of RENEWING HEALTH. <i>JMIR MHealth and UHealth</i> , 2014, 2, e52.	1.8	96
342	The organisation and delivery of health improvement in general practice and primary care: a scoping study. <i>Health Services and Delivery Research</i> , 2015, 3, 1-180.	1.4	16
343	Screening for type 2 diabetes: a short report for the National Screening Committee. <i>Health Technology Assessment</i> , 2013, 17, 1-90.	1.3	85
344	A randomised trial of the effect and cost-effectiveness of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with screen-detected type 2 diabetes: the Angloâ€Danishâ€Dutch Study of Intensive Treatment in People with Screen-Detected Diabetes in Primary Care (ADDITION-Europe) study. <i>Health Technology Assessment</i> , 2016, 20, 1-86.	1.3	12
345	Metformin in non-diabetic hyperglycaemia: the GLINT feasibility RCT. <i>Health Technology Assessment</i> , 2018, 22, 1-64.	1.3	28
346	A community-based primary prevention programme for type 2 diabetes mellitus integrating identification and lifestyle intervention for prevention: a cluster randomised controlled trial. <i>Programme Grants for Applied Research</i> , 2017, 5, 1-290.	0.4	12
347	Exploring the relationship between coronary heart disease and type 2 diabetes: a cross-sectional study of secondary prevention among diabetes patients. <i>BJGP Open</i> , 2019, 3, bjgpopen18X101636.	0.9	13
348	Comparison between sitagliptin and nateglinide on postprandial lipid levels: The STANDARD study. <i>World Journal of Diabetes</i> , 2013, 4, 8.	1.3	13
349	Effects of Thiazolidinedione and New Antidiabetic Agents on Stroke. <i>Journal of Stroke</i> , 2019, 21, 139-150.	1.4	8
350	Multiple pharmacological interventions targeting cardiovascular disease risk factors in individuals with type 2 diabetes-systematic review. <i>Journal of Diabetes Research &amp; Clinical Metabolism</i> , 2013, 2, 9.	0.2	1

#	ARTICLE	IF	CITATIONS
351	Association between weight change and remission of type 2 diabetes: a retrospective cohort study in primary care. <i>Practical Diabetes</i> , 2021, 38, 8.	0.1	4
352	Optimizing treatment goals for long-term health outcomes among patients with type 2 diabetes mellitus. <i>BMJ Open Diabetes Research and Care</i> , 2021, 9, e002396.	1.2	4
354	Nanosciences, Diabetes and the Patient. , 2012, , 380-384.		0
355	Clinical perspectives on the management of advanced stable coronary disease. , 2012, , 377-384.		0
357	The use of glucose measurements to improve screening for diabetes in clinical practice. <i>British Journal of Diabetes</i> , 2016, 16, 123.	0.1	0
358	Epidemiological Aspects and the Prevalence of Risk Factors for Type 2 Diabetes Mellitus among Residents of Almaty and Almaty Region of the Republic of Kazakhstan. <i>MÄ-Ä¼narodnij EndokrinologÄ-Änij Ä½urnal</i> , 2016, .	0.1	2
359	The diagnostic tactics of doctor of general practices regarding patient with carbohydrate metabolism disorders. <i>Shidnoevropejskij Zurnal Vnutrisnoi Ta Simejnoi Medicini</i> , 2016, 2016, 98-104.	0.0	0
360	Diabetes Management in theÄUnited States. , 2019, , 255-271.		1
361	Ä%pidÄ©miologie des Ä©tats diabÄ©tiques. , 2019, , 3-11.		0
362	Risk Assessment for Diabetes. , 2020, , 61-76.		0
363	The effect of training GPs in motivational interviewing on incident cardiovascular disease and mortality in people with screen-detected diabetes. Results from the ADDITION-Denmark randomised trial. <i>BJGP Open</i> , 2020, 4, bjgpopen20X101012.	0.9	1
364	Weight Change, Lifestyle, and Mortality in Patients With Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 627-637.	1.8	3
366	Diabetes: glycaemic control in type 2 (drug treatments). <i>Clinical Evidence</i> , 2012, 2012, .	0.2	6
367	The effect of quality of care on cardiovascular risk factors in newly diagnosed diabetic patients. <i>International Journal of Preventive Medicine</i> , 2014, 5, 1432-8.	0.2	1
369	<i>Epidemiology and Public Health</i> . , 2022, , 1946-1948.		0
370	2. Classification and Diagnosis of Diabetes: <i>Standards of Medical Care in Diabetesâ€”2022</i>. <i>Diabetes Care</i> , 2022, 45, S17-S38.	4.3	1,106
371	Risk Factors Analysis and Management of Cardiometabolic-Based Chronic Disease in Low- and Middle-Income Countries. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2022, Volume 15, 451-465.	1.1	4
372	2022 update to the position statement by Primary Care Diabetes Europe: a disease state approach to the pharmacological management of type 2 diabetes in primary care. <i>Primary Care Diabetes</i> , 2022, 16, 223-244.	0.9	15

#	ARTICLE	IF	CITATIONS
373	The long-term cost-effectiveness of oral semaglutide versus empagliflozin and dulaglutide in Portugal. <i>Diabetology and Metabolic Syndrome</i> , 2022, 14, 32.	1.2	4
374	Shared decision making in primary care: Process evaluation of the intervention in the OPTIMAL study, a cluster randomised trial. <i>Primary Care Diabetes</i> , 2022, 16, 375-380.	0.9	2
375	Changes over time in the cardiovascular risk profile of type 2 diabetes from 2007 to 2020: A community-based study. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1216-1223.	2.2	2
376	Economic evaluation of population-based type 2 diabetes mellitus screening at different healthcare settings in Vietnam. <i>PLoS ONE</i> , 2021, 16, e0261231.	1.1	2
377	Cardiovascular and renal outcomes of initial combination therapy with glucose-lowering agents versus a stepwise approach in newly diagnosed or treatment-naïve type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1469-1482.	2.2	0
378	Treatment of diabetes mellitus has borne much fruit in the prevention of cardiovascular disease. <i>Journal of Diabetes Investigation</i> , 2022, 13, 1472-1488.	1.1	2
379	Oral glucose tolerance testing as a complement to fasting plasma glucose in screening for type 2 diabetes: population-based cross-sectional analyses of 146 000 health examinations in Västerbotten, Sweden. <i>BMJ Open</i> , 2022, 12, e062172.	0.8	3
381	Long-term effects of intensive multifactorial treatment on aortic stiffness and central hemodynamics after 13 years with screen-detected type 2 diabetes: the ADDITION-Denmark trial. <i>Diabetology and Metabolic Syndrome</i> , 2022, 14, .	1.2	0
382	Ten-Year Effectiveness of the Multidisciplinary Risk Assessment and Management Programme "Diabetes Mellitus (RAMP-DM) on Macrovascular and Microvascular Complications and All-Cause Mortality: A Population-Based Cohort Study. <i>Diabetes Care</i> , 2022, 45, 2871-2882.	4.3	10
383	Recent Advances in the Emerging Therapeutic Strategies for Diabetic Kidney Diseases. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10882.	1.8	9
384	The long-term cost-effectiveness of once-weekly semaglutide 1 mg vs. dulaglutide 3 mg and 4.5 mg in the UK. <i>European Journal of Health Economics</i> , 0, , .	1.4	2
385	The societal impact of early intensified treatment in patients with type 2 diabetes mellitus. <i>Journal of Comparative Effectiveness Research</i> , 2022, 11, 1185-1199.	0.6	1
386	Once-weekly semaglutide versus insulin aspart for the treatment of type 2 diabetes in the UK: A long-term cost-effectiveness analysis based on SUSTAIN 11. <i>Diabetes, Obesity and Metabolism</i> , 2023, 25, 491-500.	2.2	4
387	<i>Epidemiology of Diabetes.</i> , 2022, , 1-49.		1
389	2. Classification and Diagnosis of Diabetes: Standards of Care in Diabetes 2023. <i>Diabetes Care</i> , 2023, 46, S19-S40.	4.3	534
390	Observational Evaluations of Disease Management Programs for Diabetes: The Proof Is in the Concept. <i>Diabetes Care</i> , 2022, 45, 2808-2810.	4.3	0
391	Efficacy and safety of intensive versus conventional glucose targets in people with type 2 diabetes: a systematic review and meta-analysis. <i>Expert Review of Endocrinology and Metabolism</i> , 2023, 18, 95-110.	1.2	0
392	Temporal relationship between atherogenic dyslipidemia and inflammation and their joint cumulative effect on type 2 diabetes onset: a longitudinal cohort study. <i>BMC Medicine</i> , 2023, 21, .	2.3	8

#	ARTICLE	IF	CITATIONS
393	Intensified Multifactorial Intervention in Patients with Type 2 Diabetes Mellitus. <i>Diabetes and Metabolism Journal</i> , 2023, 47, 185-197.	1.8	8
394	Blood pressure control for diabetic retinopathy. <i>The Cochrane Library</i> , 2023, 2023, .	1.5	6
395	CELESTIA: Cost-Effectiveness Analysis of Empagliflozin Versus Sitagliptin in Patients with Type 2 Diabetes in Greece. <i>ClinicoEconomics and Outcomes Research</i> , 0, Volume 15, 97-109.	0.7	0
396	Effect of Intensive Glycemic Control on Myocardial Infarction Outcome in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. <i>Journal of Diabetes Research</i> , 2023, 2023, 1-11.	1.0	0
397	Investigating the association between fasting insulin, erythrocytosis and HbA1c through Mendelian randomization and observational analyses. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	1
400	Diabetes Management in the United States. , 2023, , 309-328.		0